Compare SKYX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | TARA |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 165.5M |
| IPO Year | 2022 | N/A |
| Metric | SKYX | TARA |
|---|---|---|
| Price | $2.11 | $7.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $20.33 |
| AVG Volume (30 Days) | ★ 784.8K | 658.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,751,118.00 | N/A |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $28.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.06 | N/A |
| 52 Week Low | $0.88 | $2.48 |
| 52 Week High | $2.20 | $10.48 |
| Indicator | SKYX | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 73.21 |
| Support Level | $1.64 | $7.21 |
| Resistance Level | $2.10 | $7.82 |
| Average True Range (ATR) | 0.17 | 0.59 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 90.91 | 87.15 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).